Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | GLS | O94925 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1599490 | 0.78 | CETP (0.42) | CETPTACR1 | |
| SCHEMBL1600356 | 0.77 | CETP (0.42) | CETPTACR1 | |
| SCHEMBL1599481 | 0.76 | CETP (0.36) | CETPTACR1OPRM1OPRL1 | |
| SCHEMBL1600489 | 0.76 | CETP (0.37) | CETPMAPTTACR1USP2TSHR | |
| SCHEMBL27771452 | 0.75 | CYP3A4 (0.41) | CETPMAPTTACR1USP2TSHR | |
| SCHEMBL1601446 | 0.74 | TACR1 (0.41) | TACR1MGLL | |
| SCHEMBL1601402 | 0.74 | MGLL (0.38) | TACR1OPRM1OPRL1SLC6A4PTGER1 | |
| SCHEMBL1600385 | 0.74 | MGLL (0.40) | OPRM1OPRL1PTGER1MGLL | |
| SCHEMBL1599615 | 0.74 | CETP (0.41) | CETPTACR1 | |
| SCHEMBL27740295 | 0.73 | MAPT (0.45) | CETPMAPTTACR1USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919506-B2 | Dibenzyl amine compounds and derivatives | PFIZER INC. (US) | 2011-04-05 | — | — | US | disclosed |
| EP-1996564-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | Pfizer Products Incorporated (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007105050-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070213371-A1 | Dibenzyl Amine Compounds and Derivatives | PFIZER INC | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213371-A1 | Dibenzyl Amine Compounds and Derivatives | APOB, LDLR, CETP | CETP 3/4885MAPT 539/4885TACR1 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.